OWP Pharmaceuticals Announces IND Approval for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for the Treatment of Schizophrenia and Bipolar Disorder
October 07, 2020 08:00 ET
|
OWP Pharmaceuticals
NAPERVILLE, Ill., Oct. 07, 2020 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...
OWP Pharmaceuticals Announces a Second IND Approval and Patent Application: The First-Ever Liquid Oral Suspension Formulation of Lamotrigine for the Treatment of Epilepsy and Bipolar Disorder
December 03, 2019 08:00 ET
|
OWP Pharmaceuticals
NAPERVILLE, Ill., Dec. 03, 2019 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc., a privately-held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...
OWP Pharmaceuticals Announces IND Approval and Patent Application for the First-Ever Liquid Oral Suspension Formulation of Topiramate for the Treatment of Epilepsy and Migraine
November 20, 2019 08:00 ET
|
OWP Pharmaceuticals
NAPERVILLE, Ill., Nov. 20, 2019 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc., a privately-held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...